Clinical trials: HCM - Hypertrophic Cardiomyopathy
Acute Myocarditis, Dilated Cardiomyopathies
German Centre for Cardiovascular Research Cardiomyopathy Register
This is a joint project by Heidelberg University and Greifswald University. Our objective is to establish an unique national multi-center registry and biobank of well phenotyped patients with non-ischemic cardiomyopathies (CMP)…
- Conditions
- Acute Myocarditis, Dilated Cardiomyopathies, Hypertrophic Cardiomyopathies, Left Ventricular Myocardial Noncompaction Cardiomyopathy
- Trial name
- TORCH (NCT02187263)
- Where
- Germany
- Volunteers
- 2,300 people
- Sponsor
- Heidelberg University
Obstructive Hypertrophic Cardiomyopathy (oHCM)
A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
The purpose of this study is to evaluate the real-world safety and effectiveness of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) initiated on mavacamten at certain high volume HCM centers in the US
- Trial name
- NCT07107373
- Testing
- Mavacamten
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Non-obstructive Hypertrophic Cardiomyopathy, Hypertrophic Cardiomyopathy
Effect of Personalized Accelerated Pacing in Symptomatic Patients With Non-Obstructive Hypertrophic Cardiomyopathy
This will be a two-arm investigator-initiated randomized controlled study of patients with nHCM and LV ejection fraction ≥50% and NYHA II-III symptoms, normal intrinsic conduction system and pre-existing suitable dual-chamber…
- Trial name
- PACE-nHCM (NCT06775886)
- Testing
- myPACE+ algorithm
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Hypertrophic Cardiomyopathies, Athlete Heart
Role of CMR-FT in Assessment of HCM and Athlete's Heart.
Using cardiac MRI feature tracking to asses myocardial motion differences in athlete's heart and discovered hypertrophic cardiomyopathy patients to increase diagnostic accuracy of hypertrophic cardiomyopathy.
- Trial name
- NCT06859827
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sohag University
Hypertrophic Cardiomyopathy
The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.
Hypertrophic obstructive cardiomyopathy (HOCM) patients often develop disabling symptoms of heart failure. Current treatment strategies are predicated on the empirical use of long-standing drugs, such as beta-adrenergics…
- Trial name
- TEMPO (NCT03532802)
- Testing
- Metoprolol Succinate
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Steen Hvitfeldt Poulsen
Primary Cardiomyopathy, Dilated Cardiomyopathy
Risk Stratification in Children and Adolescents With Primary Cardiomyopathy
RIKADA is a prospective study performing systematic family screening including clinical and genetic testing in pediatric patients with primary cardiomyopathy and their first-degree relatives with the aim to facilitate risk…
- Conditions
- Primary Cardiomyopathy, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Left Ventricular Noncompaction
- Trial name
- RIKADA (NCT03572569)
- Where
- 2 sites in Germany
- Volunteers
- 200 people
- Sponsor
- German Heart Institute
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Evaluation of Mavacamten-Based Practice in Chinese Adults With Obstructive Hypertrophic Cardiomyopathy
The study will describe how mavacamten is used in routine care for Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), including use as monotherapy or with other background/concomitant oHCM medications.
- Trial name
- REMAP-HCM (NCT07846059)
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy
Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study
This study will test the feasibility of a modified procedure for treating obstructive hypertrophic cardiomyopathy (OHC). Patients with OHC have a thickening of the heart muscle that obstructs blood flow out of the heart, causing…
- Trial name
- NCT00035386
- Testing
- trans-right ventricular alcohol septal ablation (TRVASA)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure
The purpose of this study is to evaluate the effect of perhexiline on exercise performance (efficacy) and safety in patients with hypertrophic cardiomyopathy and moderate-to-severe heart failure following dosing for 16 weeks.
- Trial name
- NCT02862600
- Testing
- Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Heart Metabolics Limited
Fabry Disease, Fabry Disease, Cardiac Variant
Fabry Disease in High-risk Patients With Left Ventricular Hypertrophy: Prevalence and Implementation of a Clinical Score
This study aims to evaluate the prevalence of Fabry Disease (FD) among a cohort of high risk patients with left ventricular hypertrophy (LVH) presenting at the University Hospital Würzburg over the last 20 years.
- Conditions
- Fabry Disease, Fabry Disease, Cardiac Variant, Lysosomal Storage Diseases, HCM - Hypertrophic Cardiomyopathy
- Trial name
- FAPREV-HCM (NCT04943991)
- Testing
- blood sampling (alpha-Galactosidase & LysoGb3)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Wuerzburg University Hospital
Hypertrophic Cardiomyopathy
Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy
Patients with hypertrophic cardiomyopathy are being compared to a control group. IMR will be assessed with a pressure wire. Clinical f/u at 3 months and 6 months and a 48 hour holter monitor.
- Trial name
- PRIMARy (NCT02994615)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects
The purposes of this study are to: 1. Learn about the safety of CK-3773274 after a single dose and multiple doses in healthy subjects. 2. Learn how healthy subjects tolerate CK-3773274 after a single dose and multiple doses. 3.
- Trial name
- NCT03767855
- Testing
- CK-3773274 - Granules in Capsule, CK-3773274 - Tablets
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Cytokinetics
Obstructive Hypertrophic Cardiomyopathy
An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
This is an open-label extension study of China cohort in the phase 3 study (CY 6031) of aficamten for the treatment of obstructive HCM (oHCM) to collect long-term safety and tolerability data, including assessments of cardiac…
- Trial name
- NCT06116968
- Testing
- Aficamten
- Where
- 12 sites in China
- Volunteers
- 40 people
- Sponsor
- Corxel Pharmaceuticals
Hypertrophic Cardiomyopathy
Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a heart disease characterized by hypertrophy of the left ventricular myocardium and is most often caused by mutations in sarcomere genes.
- Trial name
- NCT04402268
- Testing
- Cardioverter-defibrillator
- Where
- Poland
- Volunteers
- 252 people
- Sponsor
- Poznan University of Medical Sciences
Cardiovascular Diseases, Hypertrophic Cardiomyopathy (HCM)
AI-enabled Screening and Diagnosis of Cardiomyopathies Using Coronary CTA
The goal of this observational and diagnostic study is to develop and validate an artificial intelligence assisted approach for coronary computer tomography angiography-(CCTA)-based screening and diagnosis of cardiomyopathies in…
- Conditions
- Cardiovascular Diseases, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Restrictive Cardiomyopathy
- Trial name
- Atlantis (NCT06748261)
- Testing
- CCTAI model
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Zhongshan Hospital
Hypertrophic Cardiomyopathy, Sudden Cardiac Death
PRecIsion Medicine in CardiomyopathY
This is a retrospective cohort study of pediatric hypertrophic cardiomyopathy (HCM) patients using chart and registry review methodology.
- Trial name
- PRIMaCY (NCT04036799)
- Volunteers
- 572 people
- Sponsor
- The Hospital for Sick Children
Hypertrophic Cardiomyopathy
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored…
- Trial name
- NCT06549608
- Testing
- Mavacamten
- Where
- Canada
- Volunteers
- 683 people
- Sponsor
- Bristol-Myers Squibb
Hypertrophic Cardiomyopathy (HCM)
The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
This study is a prospective interventional cohort study aimed at evaluating the therapeutic efficacy and clinical utility of Mavacamten-a targeted myosin inhibitor specifically developed for obstructive hypertrophic…
- Trial name
- BRAVE-HCM (NCT07103655)
- Testing
- mavacamten, Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol, diltiazem
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Mavacamten is a small-molecule allosteric inhibitor of cardiac myosin that reversibly inhibits its binding to cardiac actin, thereby relieving systolic hypercontractility and improving ventricular compliance.
- Trial name
- NCT05135871
- Testing
- Mavacamten
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- LianBio LLC
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
- Trial name
- FOREST-HCM (NCT04848506)
- Testing
- Aficamten (5 - 20 mg)
- Where
- 141 sites in United States, Argentina and 17 more
- Volunteers
- 900 people
- Sponsor
- Cytokinetics